Journal
MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 14, Issue -, Pages 32-40Publisher
CELL PRESS
DOI: 10.1016/j.omtn.2018.10.016
Keywords
-
Categories
Funding
- AIDS Fonds [HIV - P-37102]
- China Scholarship Council (CSC)
Ask authors/readers for more resources
The RNA-guided endonuclease Cas9 (CRISPR-Cas9) genome editing system has been widely used for biomedical research and holds great potential for therapeutic applications in eukaryotes. The conventional vector-based CRISPR-Cas9 delivery system requires two different RNA polymerase promoters for expression of the guide RNA (gRNA) and Cas9 endonuclease. The large size and relative complexity of such CRISPR transgene cassettes impede their broad implementation, especially in gene therapy applications with viral vectors that have a limited packaging capacity. Here, we report the design of a single-promoter-driven CRISPR-Cas9 system that uses the dualpolymerase (Pol II and Pol III) activity of the H1 promoter. This size reduction strategy of the vector insert provides a significant titer advantage in the lentiviral vector over the regular CRISPR system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available